CNS biotech MapLight Therapeutics eyes $175M raise for PhII clinical trials in schizophrenia, autism and Parkinson’s

MapLight Therapeutics, a biotech focused on central nervous system disorders, is eyeing a large $175 million financing as it beefs up the C-suite and advances multiple drug candidates. The biotech has so far raised $50 million from five investors in the offering, per a Wednesday SEC Click here to view original post